Editas Medicine is a gene editing company developing genomic medicines based on CRISPR technology to treat serious genetic diseases. The company operates a proprietary platform encompassing CRISPR/Cas9, CRISPR/Cas12a, and engineered variants with modular delivery capabilities including lipid nanoparticle systems, enabling in vivo gene editing across the majority of the human genome. Its lead candidates include EDIT-401 for hyperlipidemia and in vivo therapies for hemoglobinopathies like sickle cell disease, alongside partnerships with Bristol Myers Squibb, Vertex Pharmaceuticals, and Immatics that advance cell therapies and generate revenue through upfront payments, milestones, royalties, and out-licensing of intellectual property. Editas targets large patient populations with serious genetic diseases and currently generates revenue primarily from partnership agreements rather than product sales.